drugset / Trial / NCT05909488
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
Timeline
- Start
- 2026-05
- Primary completion
- 2027-07
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 1.5e+06 cells | Other |
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 5e+06 cells | Other |